GLA in Echocardiography Context
I need to clarify that "GLA" on an echocardiogram does not refer to a standard echocardiographic measurement or parameter. The term GLA in cardiology literature refers to the galactosidase A (GLA) gene, which when mutated causes Fabry disease—a condition that can manifest with cardiac abnormalities detectable on echocardiography 1.
What GLA Actually Represents
GLA is the gene encoding α-galactosidase A enzyme, deficiency of which causes Fabry disease, an X-linked lysosomal storage disorder 1. When you encounter "GLA" in the context of cardiac imaging:
- GLA gene mutations lead to deficient α-galactosidase A enzyme activity, causing accumulation of globotriaosylceramide (Gb3) in cardiac tissue 1, 2
- This accumulation results in left ventricular hypertrophy (LVH) that is visible on echocardiography 2, 3
- The cardiac manifestations include progressive cardiomegaly, arrhythmias, and heart failure 2
Echocardiographic Findings in GLA-Related Disease
When GLA mutations cause Fabry cardiomyopathy, echocardiography reveals:
- Left ventricular wall thickening (interventricular septum and posterior wall hypertrophy) 4
- Increased left ventricular mass 4
- Preserved systolic function initially with mildly abnormal diastolic function 4
- Specific pattern of hypertrophy that may be distinguished from other causes of hypertrophic cardiomyopathy using advanced techniques like strain imaging 2, 3
Clinical Context
If you're seeing "GLA" referenced in an echocardiography report, it likely indicates:
- The patient is being evaluated for or has confirmed Fabry disease due to GLA gene mutations 5, 6
- Screening for cardiac involvement in a patient with known or suspected GLA variants 6, 4
- The echocardiogram is being used to monitor cardiac manifestations of Fabry disease 2, 3
Key Diagnostic Considerations
- GLA gene screening should be considered in patients with unexplained hypertrophic cardiomyopathy, particularly when sarcomeric mutations are absent 6, 4
- Diagnosis requires enzymatic testing (α-Gal A activity in plasma or leukocytes in males) and genetic confirmation of GLA mutations 1
- Cardiac-specific variants of Fabry disease (like N215S) can present with isolated cardiac hypertrophy without prominent extracardiac manifestations, making diagnosis challenging 4